JP Morgan Cazenove Reiterates British American Tobacco p.l.c. (BTAFF) Neutral Recommendation

JP Morgan Cazenove reiterated a Neutral on British American Tobacco on Nov. 26, 2025, while consensus analyst targets (as of Nov. 17) imply a one-year average price target of $58.47 — ~92.27% above the last close of $30.41 — with a range of $39.59–$71.33. Analysts project annual revenue of $31,287MM (up 22.23%) and non-GAAP EPS of 4.49; institutional interest is rising with 455 funds reporting positions, total institutional shares up 3.63% to 641,508K and average fund weight at 0.89% (up 10.31%). The note is informational and bullish on price upside but carries a Neutral analyst rating, suggesting upside is priced on forecasts rather than a change in company guidance.

Analysis

Market structure: A successful re-rate of British American Tobacco (BTI / OTC:BTAFF) primarily benefits equity holders, bondholders (credit spreads tightening) and suppliers of reduced-risk products; large tobacco peers (PM, IMBBY) may see relative underperformance if BAT captures premiumization share. Pricing power remains intact in markets with inelastic demand for combustibles, but volume risk from tax hikes or plain‑packaging shifts margin leverage to pricing and portfolio mix (heated tobacco, vapes). Cross-asset: a sustained equity rally would compress BTI CDS and push sovereign/FX sensitivity higher (GBP/USD moves >3% will materially change USD-reported revenue).

Risk assessment: Tail risks include accelerated regulatory bans on flavored/non-combustible products, large litigation losses, or a 100–200bp excise shock in key markets — each could erase >30% equity value in quarters. Immediate (days) risk is sentiment and fund flows; short-term (weeks–months) risk is Q4 trading/earnings and FX; long-term (quarters–years) is product mix transition and litigation. Hidden dependencies: earnings hinge on non-GAAP EPS realization of $4.49 and buyback/dividend capacity; currency and cigarette illicit trade are second-order profit drivers. Key catalysts: FY results, EU/US regulatory announcements, and large fund filings within 30–90 days.

Trade implications: Direct: consider establishing a 2–3% long position in BTI (or OTC:BTAFF) with a 12‑month target ~$58 and a stop-loss at a close below $26 (~15% downside). Options: buy Jan 2027 $35 LEAP calls (allocation 0.5–1% portfolio) or use a 30/50 call spread to cap cost; alternative sell Jan 2026 $28 cash‑secured puts to acquire at a net cost basis ~28 with R/R skew. Relative: pair trade long BTI vs short PM to capture potential multiple convergence (BTI P/E ~6.8x vs peers ~12–14x).

Contrarian angles: The 92% average PT upside is model-driven and ignores regulatory tail risk — upside may be underpriced if EPS 4.49 is delivered and buybacks resume: moving to a 10–12x multiple implies $45–54 in 12–18 months. Conversely, consensus underestimates rapid regulatory tightening risk; if governments accelerate bans, downside could exceed modeled scenarios. Historical parallels (2019–21 re‑rating around reduced‑risk products) show outcomes hinge on execution; monitor net revenue growth vs. guidance for the next two quarters as a make-or-break signal.

Key Decisions for Investors

• Establish a 2–3% long position in BTI (NYSE:BTI or OTC:BTAFF) using limit orders around $29–31; set a 12‑month target of $58 and an absolute stop-loss to cut position on a daily close below $26.
• Allocate 0.5–1% of portfolio to Jan 2027 $35 LEAP calls on BTI (or buy a 30/50 call spread to cap cost) to express asymmetric upside toward the $58 analyst consensus while limiting capital outlay.
• Sell Jan 2026 $28 cash‑secured puts size 1–2% notional to acquire BTI at ~28 net cost; immediately reduce if implied volatility rises >30% or if regulatory negative headlines surface.
• Implement a pair trade: long BTI (1–2%) and short PM (0.5–1%) to capture valuation convergence; rebalance monthly and unwind if BTI P/E >10x or PM outperforms by >10% in 60 days.
• If institutional ownership trends reverse (quarterly institutional selling >5% net) or a major regulatory action is announced (EU/US policy within 30–90 days), exit long positions and convert to cash or hedged exposure.